RxDoctor Payments Data

Ruben Pinero Fuentes, MD

Psychiatry · Brownsville, TXNPI 1710326046

Payments from drug & device makers

$74,215in general payments, 2019–2025

Across 223 payments — averaging $332.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$41K
  • Neurocrine Biosciences, Inc.$30K
  • Otsuka America Pharmaceutical, Inc.$830
  • Johnson & Johnson$674
  • AbbVie$657
  • Alkermes, Inc.$528
  • plus $578 from 11 others

What the payments were for

  • Consulting fees$6,2008%
  • Speaking & faculty fees$56,52276%
  • Travel & lodging$5,5147%
  • Food & beverage$5,8678%
  • Education$1110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,215 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$5,114
Medicare patients
14
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate73$235,585
IngrezzaValbenazine Tosylate19$163,140
Austedo XrDeutetrabenazine11$56,394
LybalviOlanzapine/Samidorphan Malate46$52,965
PerserisRisperidone15$44,266
Clozapine86$10,824
Clozapine OdtClozapine16$6,557
Haloperidol Decanoate57$4,527
Trazodone Hcl186$3,967
Divalproex Sodium ErDivalproex Sodium62$3,544
Paliperidone ErPaliperidone15$2,007
Quetiapine Fumarate74$1,748
Benztropine Mesylate127$1,433
Bupropion XlBupropion Hcl75$1,268
Hydroxyzine Hcl62$1,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$674$235,58573 claims
Neurocrine Biosciences, Inc.Ingrezza$30,389$163,14019 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$40,559$56,39411 claims
Alkermes, Inc.Lybalvi$528$52,96546 claims
Indivior Inc.Perseris$36$44,26615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →